Source: CureToday articles
Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple settings in EGFR-mutated NSCLC.
Recent Content
- You Are Not Alone While Building a Support Team During Cancer Care
- Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma
- When Treatment Ends, Support Shouldn’t Stop in Cancer Care
- Sequencing Strategies and the Role of Combination Therapy
- Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
- Being in the Present Moment With Multiple Myeloma
- Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis
- ASCO 2025: Fixed-Duration Treatment Emerges as Future of Multiple Myeloma Management
- ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC
- Maximizing Your Pharmacy Fellowship Experience: Tips for Success